Opinion

Video

Managing Hematologic AEs Associated with ADC Treatments

Author(s):

VK Gadi, MD, PhD,Susana M. Campos, MD, MPH

A panel of experts discuss hematologic adverse events associated with antibody-drug conjugate therapies.

Related Videos
1 expert in this video
1 expert in this video
Guru P. Sonpavde, MD
Mary B. Beasley, MD, discusses molecular testing challenges in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the multidisciplinary management of NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of pathologists in molecular testing in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of RNA and other testing considerations for detecting NRG1 and other fusions in solid tumors.
Mary B. Beasley, MD, discusses the prevalence of NRG1 fusions in non–small cell lung cancer and pancreatic cancer.
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Related Content
Diffuse Glioma
November 25th 2024

Perioperative Vorasidenib and Ivosidenib Remain Effective, Safe in IDH1+ Diffuse Glioma

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Natural Killer Cells in Ovarian Cancer | Image Credit: © Dr_Microbe - stock.adobe.com
November 18th 2024

First Clinical Trial of “Memory Like” Natural Killer Cells in Ovarian Cancer Opens at Dana-Farber

Narjust Florez, MD
September 5th 2024

Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions

Matthew Vander Heiden, MD, PhD
November 1st 2024

Two Dana-Farber Cancer Institute Faculty Members Elected to the National Academy of Medicine

Coleman Lindsley, MD, PhD
October 28th 2024

Rapid Blood Cancer Diagnostic Could Speed Decisions and Save Lives